The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases
Cardiovascular Drugs and Therapy · 2023-08 · 37 (4) · 757-770
DOI: 10.1007/s10557-021-07248-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 17.09.2021. Verfasst von Martin H Strauss und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, North York General Hospital, Toronto, ON, Canada. martin.strauss@nygh.on.ca. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hypertension, Heart Failure. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servier.
Abstract (Originalsprache)
Cardiovascular disease is the leading cause of mortality worldwide, affecting a wide range of patients at different stages across the cardiovascular continuum. Hypertension is one of the earliest risk factors in this continuum and can be controlled in most patients with currently available antihypertensive agents. However, goals are often not met because treatments are not optimized in terms of tailoring therapy to individual patients based on their hypertension subclass and cardiovascular risk profile and initiating early use of adapted-dose, single-pill combinations. In this context, beta-blockers in combination with angiotensin-converting enzyme (ACE) inhibitors are of special interest as a result of their complementary actions on the sympathetic nervous system and renin–angiotensin–aldosterone system, two interlinked pathways that influence cardiovascular risk and disease outcomes. In addition to their antihypertensive actions, beta-blockers are used to manage arrhythmias and treat angina pectoris and heart failure, while ACE inhibitors provide cardioprotection in patients with acute coronary syndromes and treat congestive heart failure. A broad range of patients may therefore receive the combination in routine clinical practice. This paper examines the supporting evidence for beta-blockers and ACE inhibitors in each of the above indications and considers the rationale for combining these agents into a single pill, using data from bisoprolol and perindopril randomized controlled trials as supporting evidence. Combining these established antihypertensive agents into a single pill continues to provide effective blood pressure lowering and improved cardiovascular outcomes while allowing a greater proportion of patients to rapidly achieve treatment targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Toronto, North York General Hospital, Toronto, ON, Canada. martin.strauss@nygh.on.ca.
- Leeds School of Medicine, University of Leeds, Leeds, UK.
- Department of Hypertension and Diabetology, Faculty of Medicine, Medical University of Gdansk, Debinki 7c, 80-952, Gdansk, Poland.
Förderung
- Servier
Zitieren
APA
Strauss, M. H., Hall, A. S., & Narkiewicz, K. (2023). The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. Cardiovascular Drugs and Therapy, 37(4), 757-770. https://doi.org/10.1007/s10557-021-07248-1
Vancouver
Strauss MH, Hall AS, Narkiewicz K. The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. Cardiovascular Drugs and Therapy. 2023;37(4):757-770. doi:10.1007/s10557-021-07248-1
BibTeX
@article{Strauss2023,
author = {Strauss, Martin H and Hall, Alistair S and Narkiewicz, Krzysztof},
title = {The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases},
journal = {Cardiovascular Drugs and Therapy},
year = {2023},
volume = {37},
number = {4},
pages = {757--770},
doi = {10.1007/s10557-021-07248-1}
}
EUVIMED